Brief: Apexigen Announces Positive Interim Results From Phase 2 Trial
14/11/2022 13:19
Nov 14 (Reuters) - Apexigen Inc APGN.O :
* APEXIGEN ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2
TRIAL
EVALUATING ITS CD40 ANTIBODY, SOTIGALIMAB, IN COMBINATION WITH
DOXORUBICIN IN PATIENTS WITH LIPOSARCOMA
* APEXIGEN INC - PATIENTS WITH LPS SHOWED PROLONGED MEDIAN
PFS
(MPFS) RELATIVE TO HISTORICAL CONTROLS TREATED WITH STANDARD OF
CARE OF DOXORUBICIN
Source text for Eikon: ID:nGNXKZyRP
Further company coverage: APGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq